This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Ocrevus
  • /
  • A Study of Ocrelizumab in Children and Adolescents...
Clinical trial

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Read time: 1 mins
Last updated:28th Aug 2023
Status: RECRUITING
Identifier: NCT04075266
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis


ClinicalTrials.gov ID/ NCT04075266

Sponsor: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche (Responsible Party)
Last Update Posted: 2023-08-29

Brief Summary:
This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.

OFFICIAL TITLE
An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

INTERVENTION / TREATMENT
Drug: Ocrelizumab

Category Value
Study Start (Actual) 2020-01-09
Primary Completion (Estimated) 2023-12-31
Study Completion 2029-12-01
Enrollment (Estimated) 36
Study Type Interventional
Phase Phase 2
Other Study ID Numbers WA39085
2016-002667-34 ( EudraCT Number )

View full details